yes but the one i focused on, functional cure, is actually being pursued. monotherapy is not being pursued. tough to transform without being part of the company pipeline. i'm not sure whether NASH is a great fit for limited resources tbh. i like the idea of pancreatic cancer instead of NASH. and/or a combination approach in oncology. revolutionary weight loss drugs might significantly reduce the TAM for NASH. and imminent approvals in NASH will set the bar high. also, CCR5 blockers have dosing limitations for NASH. the ccr5 literature indicates oncology being a better fit for ccr5 blocking than NASH.